Objective: To determine the range of fluctuation in total lymphocyte counts (TLCs) in peripheral blood over a 4-to 7-year period in patients with MS receiving fingolimod (FTY720) and the relation between TLCs and T-cell subsets (CD41, CD81, CCR71/2) that are differentially regulated in the lymph nodes by fingolimod.
Results: All serially studied patients had mean TLCs ,0.6 3 10 9 lymphocytes/L. In 30% of patients, 20% to 40% of TLCs were .0.6 3 10 9 lymphocytes/L vs mean 4.0% for "nonfluctuator" patients. Cross-sectional analysis indicated that TLCs of 0.2-0.6 3 10 9 lymphocytes/L correlated with numbers of CD81 effector (CCR72) cells. For patients discontinuing therapy, TLCs between 0.6 and 1.0 3 10 9 lymphocytes/L were associated with a relative increase of CD4 T cells and reappearance of CCR71 (CD41 and CD81) T cells. Analysis of cryopreserved mononuclear cell samples from patients receiving therapy with TLCs .0.6 3 10 9 lymphocytes/L indicated no differences in total CD4 or CD81 T cells but increased proportion of CD41CCR71 T cells compared to samples with TLCs ,0.6 3 10 9 lymphocytes/L.
Conclusion:
Fluctuations of TLCs within 0.2-0.6 3 10 9 lymphocytes/L in patients receiving fingolimod reflect changes in total CCR72CD81 effector cells, a population less regulated by this agent. Although less apparent than for patients discontinuing therapy, cells expected to be sequestered by this therapy may begin to re-emerge when TLC values are .0.6 3 10 9 lymphocytes/L. Neurology ® 2013;81:1768-1772 GLOSSARY LN 5 lymph node; S1P 5 sphingosine 1-phosphate; TLC 5 total lymphocyte count.
Fingolimod (FTY720) decreases expression of sphingosine 1-phosphate (S1P) receptors on lymphocytes. This inhibits their egress from regional lymph nodes (LNs), resulting in peripheral blood lymphopenia. 1 Lymphocyte trafficking between the peripheral circulation and LNs is regulated by a balance of homing signals, including those recognized by chemokine receptor CCR7, and egress signals mediated by S1P. 1, 2 Lymphocyte retention in LNs is most apparent for CCR7-expressing T cells (naive and central memory) and least for CCR72 effector memory cells 3 ; the latter are more numerous within the CD81 than the CD41 population, accounting for their greater contribution to the remaining circulating lymphocyte pools. 1, 4, 5 Phase III clinical trials with fingolimod included daily doses of 1.25 mg and 0.5 mg, but 0.5 mg is the currently approved dose. 4 No differences in clinical or MRI efficacy outcomes were observed between doses. Although no significant concerns about infections were identified, recent reports raise issues regarding the impact of peripheral lymphopenia on susceptibility to infection, especially herpes virus-related. 6 We address the range of fluctuation in total lymphocyte counts (TLCs) in peripheral blood in patients receiving fingolimod for up to 7 years and relate this to T-cell populations (CD41, CD81, CCR71/2) whose egress from the LNs is differentially regulated by CCR7/S1P-related signals. We compare this relation of TLCs and T-cell subsets with that found in individuals who reconstitute their peripheral lymphocyte pool while temporarily discontinuing therapy.
METHODS Serial studies of TLCs. TLCs of patients participating in extension phases of the Novartis 2201 (5.0 mg or 1.25 mg vs placebo) 7 and 2302 (1.25 mg or 0.5 mg vs placebo) studies 8 were measured on whole-blood samples every 3 months for up to 7 years (n 5 9) and 4 years (n 5 14), respectively, by standard commercial labs. Trial entry criteria required all patients to have a normal range of TLCs (1.4-4.0 or 0.8-2.8 3 10 9 lymphocytes/L). During the extension phase, patients were placed on a 1.25-mg or 0.5-mg daily dose as indicated in figure 1. Patients were categorized in "fluctuator" vs "nonfluctuator" subgroups based on the percentage of their TLC measurements exceeding 0.6 3 10 9 lymphocytes/L. No patient had a mean TLC .0.6 3 10 9 lymphocytes/L. Patients with an individual standard deviation (SD) of TLCs larger than the SD of TLCs for the whole cohort were found to have .10% (20%-40%) of TLCs .0.6 3 10 9 lymphocytes/L whereas patients with a below average SD for TLCs had ,10%.
Lymphocyte subset analyses. Cross-sectional subset analyses were performed on whole-blood samples from all patients continuing in the extension trial (4 were tested twice), and an additional 4 patients receiving therapy as part of clinical practice (n 5 31 total samples). Controls included healthy volunteers and untreated patients with MS (n 5 20). T cells were analyzed in whole-blood specimens by immunostaining with CD4-FITC, CD8-PerCP, and CCR7-AlexaFluor647 (BD Biosciences, Franklin Lakes, NJ) antibodies. Data were acquired using a FACSCalibur (Becton Dickinson Immunocytometry Systems, San Jose, CA) and analyzed with FlowJo software (Tree Star, Ashland, OR). Similar analyses were performed on patients who transiently discontinued therapy because of clinical side effects (e.g., headache, pharyngitis), as well as on mononuclear cells recovered from cryopreserved samples that were collected during the trial. 9
Standard protocol approvals, registrations, and patient consents. Relation of T-cell subset and TLCs <0.6 3 10 9 lymphocytes/L. Although the 31 whole-blood samples included in our cross-sectional T-cell subset analysis were obtained from fluctuator and nonfluctuator subgroups, all had TLCs ,0.6 3 10 9 lymphocytes/L at collection time. The CD8 to CD4 T-cell ratio was increased compared with controls (8:1 vs 1:2 for controls, n 5 20) ( figure 2 ). This increased ratio was even more apparent in patients with TLCs of .0.4 3 10 9 lymphocytes/L (10:1) compared to those with TLCs of ,0.4 3 10 9 lymphocytes/L (7:1). The proportion of CCR71 cells in both the CD81 (3.0% 6 2.0%) and CD41 (10.1% 6 4.2%) T-cell subsets was significantly reduced compared with control values (33.1% 6 13.5% for CD81 T cells, p , 0.001; 60.1% 6 11.1% for CD41 T cells, p , 0.001). Thus, over this TLC range, the CD81CCR72 population remained the dominant contributor to the T-cell pool (.85%).
Relation of T-cell subset and TLCs (0.6-1.0 3 10 9 lymphocytes/L) in patients discontinuing therapy. These whole-blood sample data were derived from 3 individuals discontinuing therapy ( figure 3A) . For the 5 available samples with TLCs of 0.6-1.0 3 10 9 lymphocytes/L, mean percentage total CD41 T cells (24.5% 6 3.9%) was increased compared with the 4 available samples with TLCs ,0.6 3 10 9 lymphocytes/L from these same donors (12.9% 6 3.1%, p 5 0.06). Total percentage CD81 T cells was not different (30.2% 6 2.4% and 26.5% 6 6.1%). The mean proportion of CCR71 cells in the CD41 (37.4% 6 8.4%) and CD81 (16.4% 6 3.2%) T-cell populations for TLCs .0.6 3 10 9 lymphocytes/L was increased compared with CD41 (12.5% 6 2.5%) and CD8 (6.6% 6 1.2%) T cells for TLCs ,0.6 3 10 9 lymphocytes/L (all p , 0.05).
Relation of T-cell subset and TLCs >0.6 3 10 9 lymphocytes/L in patients receiving long-term therapy.
These data were derived from 10 cryopreserved samples with TLCs on the collection date of .0.6 3 10 9 lymphocytes/L and compared with 8 samples with TLCs of ,0.6 3 10 9 lymphocytes/L ( figure 3B) . Samples from 4 donors were included in both groups. For samples with TLCs .0.6 3 10 9 lymphocytes/L, mean percentage total CD41 (9.6% 6 1.9%) and CD8 (39.5% 6 3.1%) T cells did not differ from samples with TLCs ,0.6 3 10 9 lymphocytes/L (16.0% 6 2.8% for CD4, 34.6% 6 3.0% for CD8). The mean proportion of CCR71 cells in the CD41 and CD81 T-cell populations was increased in the TLCs .0.6 3 10 9 lymphocytes/L samples (CD41CCR71 37.9% 6 6.6% vs 59.6% 6 5.4%, p 5 0.02; CD81CCR71 19.0% 6 2.6% vs 28.9% 6 5.2%, p 5 0.1). DISCUSSION This study indicates that at both the 0.5-mg and 1.25-mg doses of fingolimod, up to 30% of patients have repeated fluctuations in their TLCs to values .0.6 3 10 9 lymphocytes/L. However, no patient had a mean TLC .0.6 3 10 9 lymphocytes/L. Differences in TLCs did not correlate with serum drug levels provided by Novartis. We did not identify any link between fluctuations in TLCs and clinical disease activity or serious adverse events. Our cross-sectional T-cell subset analysis from patients with TLCs in the 0.2 to 0.6 3 10 9 lymphocytes/L range showed that CD81 effectors (CD81CCR72) were the dominant T-cell population throughout this range. This is consistent with observations that such CCR72 cells are less regulated by S1P gradients. CD41 and CD81 cells accounted for approximately 45% of the total lymphocyte population; the remaining cells would predominantly be natural killer cells. 10 For patients with TLCs between 0.6 and 1.0 3 10 9 lymphocytes/L when withdrawing from therapy, there was reappearance of cells (CD41 T cells, CCR71 T cells) expected to be sequestered by the therapy and implicated both in disease pathogenesis and host defense. The finding of this rapid reconstitution of CCR71 cells, a population that includes Th17 central memory cells, 1 raises caution about temporary drug holidays used to evaluate possible drug-induced secondary effects or to permit transition to other therapies. Although the profile of lymphocytes in patients with TLCs .0.6 3 10 9 lymphocytes/L while receiving therapy does not recapitulate that of patients discontinuing therapy, our results suggest that cells expected to be sequestered by this therapy (CCR71) are beginning to re-emerge.
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Figure 2
Lymphocyte subset analysis in whole blood of fingolimod-treated patients
Cross-sectional analysis of whole-blood samples of patients receiving therapy showing mean percentage CD81 and CD41 lymphocytes (A), CD81CCR71 and CCR72 cells (B), and CD41CCR71 and CCR7-cells (C) in relation to total lymphocyte counts (TLCs) in fingolimod-treated patients and controls.
